| Date | Title | Description |
| 13.08.2026 | Tenosynovial Giant Cell Tumor Treatment Market to Witness Robust Growth Driven by Precision Medicine and Targeted Oncology Innovation | Overview
According to DataM Intelligence, the global tenosynovial giant cell tumor treatment market size reached USD 8.88 billion in 2025 and is forecast to reach USD 13.40 billion by 2035, expanding at a CAGR of 4.2% during the 2026–2035 f... |
| 16.11.2025 | Scripta Therapeutics Transforms Disease Treatment with $12M Investment | Scripta Therapeutics, an Oxford-based techbio startup, has raised $12 million in seed funding. This capital propels its innovative biology-first platform. The system leverages AI, advanced imaging, and patient-derived models. It precisely t... |
| 14.11.2025 | Scripta Therapeutics Raises $12M in Seed Funding | Scripta Therapeutics, an Oxford, UK-based techbio startup, raised $12m in seed funding.
The round was led by Oxford Science Enterprises and Apollo Health Ventures, with participation from AlbionVC, YZR Capital, and Parkwalk Advisors, and su... |
| 12.11.2025 | The UK’s Scripta Therapeutics raises over €10 million to “flip the script” on drug discovery | Oxford BioTech startup Scripta Therapeutics emerges from stealth today by announcing a €10.3 million ($12 million) Seed round to upend conventional approaches to drug discovery.
The round is led jointly by Oxford Science Enterprises (OSE) a... |
| 24.04.2025 | SynOx Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for Emactuzumab for Tenosynovial Giant Cell Tumours (TGCT) | DUBLIN, Ireland and OXFORD, United Kingdom, April 14, 2025 (GLOBE NEWSWIRE) — SynOx Therapeutics Limited (“SynOx”), a late-stage clinical biopharmaceutical company developing of emactuzumab for Tenosynovial Giant Cell Tumours (TGCT), today ... |
| 24.04.2025 | SynOx Therapeutics Announces Board Chair Transition to Align with Advancing Regulatory and Commercialization Strategy | Newly Appointed Board Chair, Philip Astley-Sparke, Brings Transatlantic Late-Stage Development, Regulatory and Commercial Expertise
Strengthened Leadership and Expanded U.S. Presence Positions SynOx for Regulatory Filings and Commercializat... |
| 13.01.2025 | Forbion promotes Dirk Kersten to Managing Partner and strengthens US team | • Dirk Kersten promoted to Managing Partner, further strengthening firm’s leadership
• Jonathan McNeill, M.D. joins Forbion as Partner in the Boston office
Naarden, The Netherlands – 13 January 2025 - Forbion, a leading global life sciences... |
| 22.12.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors
Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 31.10.2024 | SynOx Therapeutics: A New Dawn in Cancer Treatment | In the world of biopharmaceuticals, every breakthrough feels like a beacon of hope. SynOx Therapeutics, a late clinical-stage company based in Dublin and Oxford, has recently raised a staggering $92 million in its Series B financing round. ... |
| 30.10.2024 | SynOx Therapeutics Adds New Investor and Capital to Series B Financing, Raising Total to $92 Million, and Doses First Patients in Phase 3 Trial | Gilde Healthcare Leads Series B Extension, Joining Premier Syndicate of Leading Life Science Investors
Funding Supports Registrational Phase 3 TANGENT Trial of Emactuzumab, a Best-in-Class CSF-1 Receptor Targeted Antibody, for the Treatment... |
| 30.10.2024 | Dublin-based SynOx adds new capital to Series B, raising total to €84.8 million | SynOx, a late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, announced that it has raised additional funding in a final close of its Series B financing. The Series B ... |
| 30.10.2024 | SynOx Therapeutics Raises Additional Funding in Series B Round; Total to $92M | SynOx Therapeutics, a Dublin, Ireland- and Oxford, UK-based late clinical-stage biopharmaceutical company developing a novel treatment for CSF-1 related and macrophage-driven disorders, raised additional funding in Series B round.
The round... |
| 07.09.2024 | SynOx Therapeutics: Pioneering a New Era in Cancer Treatment | In the world of biopharmaceuticals, innovation is the lifeblood. SynOx Therapeutics, a late-stage clinical company based in Dublin and Oxford, is making waves with its promising drug, emactuzumab. This monoclonal antibody targets Tenosynovi... |
| 07.09.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital | • SynOx is developing emactuzumab – a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
• Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 07.09.2024 | SynOx Therapeutics announces $75m Series B round to fund Phase 3 trial of potential best-in-class treatment for TGCT | Dublin, Ireland and Oxford, UK, 22 April 2024: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, is pleased to announce the close of a $75m Series B financing. The financing was co-led... |
| 30.04.2024 | SynOx Therapeutics Raises Up To $35M in Debt Financing | SynOx Therapeutics Limited, a Dublin, Ireland- and Oxford, UK-based late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, raised up to $35M in Deb... |
| 30.04.2024 | SynOx Therapeutics secures up to $35m debt financing with Hercules Capital to progress development and commercialisation of emactuzumab | • SynOx is developing emactuzumab - a potential best-in-class, next-generation CSF1(R) inhibiting monoclonal antibody
• Provides flexible loan facility to support additional clinical work and activities to drive its successful registration ... |
| 23.04.2024 | SynOx Therapeutics: Revolutionizing TGCT Treatment with Emactuzumab | SynOx Therapeutics Limited, a clinical biopharmaceutical company, has secured a whopping $75 million in Series B financing to advance the development of Emactuzumab, a groundbreaking monoclonal antibody for the treatment of Tenosynovial Gia... |
| 22.04.2024 | SynOx Therapeutics Raises $75M in Series B Funding | SynOx Therapeutics, a Dublin, Ireland and Oxford, UK-based late-stage clinical biopharmaceutical company, closed a $75m Series B financing.
The round was co-led by Forbion, HealthCap and new investor Bioqube Ventures. As part of the Series ... |
| 22.04.2024 | Forbion co-leads $75m Series B Financing in SynOx Therapeutics | •Financing co-led by Forbion, HealthCap and new investor Bioqube Ventures
•Funds will be used for pivotal trial of potential best-in-class, next-generation treatment for Tenosynovial Giant Cell Tumour
Dublin, Ireland and Oxford, UK, 22 Apri... |
| 01.09.2022 | Emactuzumab designated as an Orphan Medicinal Product in Europe | Dublin, Ireland, 31 August 2022: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company, announces a regulatory update on emactuzumab, in development for the treatment of Tenosynovial Giant ... |
| 12.01.2022 | SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer | Dublin, Ireland, August 3, 2021: SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumours (TGCT), today announces th... |
| 19.11.2020 | SynOx raises €37M to advance ex-Roche drug in rare tumor type | SynOx Therapeutics has raised €37 million ($44 million) to advance a drug licensed from Roche. The series A tees SynOx up to build on signs the anti-CSF1R monoclonal antibody improves outcomes in patients with tenosynovial giant cell tumors... |
| 19.11.2020 | SynOx Therapeutics raises €37M in Series A Financing | DUBLIN, Nov. 19, 2020 /PRNewswire/ — SynOx Therapeutics Ltd (“SynOx”), a clinical stage bio pharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forb... |
| - | SynOx Therapeutics | “Synox | Website – Synox | Website” |
| - | SynOx Therapeutics: Clinical Biopharmaceutical Company Raises $75 Million To Develop Emactuzumab | SynOx Therapeutics Limited – a late-stage clinical biopharmaceutical company – announced today the closing of a $75 million Series B financing. The funding was co-led by Forbion, HealthCap, and new investor Bioqube Ventures.
The proceeds of... |
| - | SynOx Therapeutics: $35 Million In Debt Financing Raised From Hercules Capital | SynOx Therapeutics, a late-stage clinical biopharmaceutical company developing emactuzumab for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other diseases, announced it has entered into a $35 million loan facility with Hercule... |
| - | SynOx Therapeutics raises €37M in Series A Financing | Dublin, Ireland, November 19, 2020 –SynOx Therapeutics Ltd (“SynOx”), a clinical stage biopharmaceutical company, announces today the closing of a €37 million Series A financing co-led by HealthCap and Medicxi and joined by investors Forbio... |
